Health Digest on MSN1y
The Jardiance Commercial Explained: Drug Uses, Side Effects, And MoreThe Food and Drug Administration approved Jardiance (empagliflozin) as a once-daily oral tablet to treat type 2 diabetes in ...
Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease in a clinical trial, and is now on course to be the first to have a chronic ...
The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin) within 14 days of an acute myocardial infarction (AMI) reduced the risk of a ...
Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Hosted on MSN16d
Health Rounds: Ingested plastic particles head for the brainIn pigs receiving anthracyclines, the researchers administered a 20 mg daily dose of the SGLT2 inhibitor empagliflozin, sold as Jardiance by Boehringer Ingelheim. Empagliflozin increases the heart ...
Compared with empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), dapagliflozin produced a similar impact on MI/stroke risk but was associated with an increased risk of heart failure (HF) ...
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Boehringer Ingelheim Pharmaceuticals Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback